Ledger.Open graph →

SEC Form D · filed March 28, 2016

Chase Pharmaceuticals Corp

Offering

$12.0M

Sold

$12.0M

Exemption

Rule 506(b)

Industry

Pharmaceuticals

Location

WASHINGTON, Washington, D.C.

Type

—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (16)

Kathleen N. Clarence-Smith · Washington, Washington, D.C.Exec Vikram M. Sudarsan · Washington, Washington, D.C.Director Raphael M. Wisniewski · Washington, Washington, D.C.Director Stephen N. Cunningham · Washington, Washington, D.C.Director Nayan G. Parekh · Washington, Washington, D.C.Director Karoly N. Nikolich · Washington, Washington, D.C.Director John M. Reher · Washington, Washington, D.C.Director Thomas N. Chase · Washington, Washington, D.C.Exec · Director Kathleen N. Clarence-Smith · Washington, Washington, D.C.Exec Vikram M. Sudarsan · Washington, Washington, D.C.Director Raphael M. Wisniewski · Washington, Washington, D.C.Director Stephen N. Cunningham · Washington, Washington, D.C.Director Nayan G. Parekh · Washington, Washington, D.C.Director Karoly N. Nikolich · Washington, Washington, D.C.Director John M. Reher · Washington, Washington, D.C.Director Thomas N. Chase · Washington, Washington, D.C.Exec · Director

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗